Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.
adverse events
chronic lymphocytic leukemia
ibrutinib
rituximab
treatment
unfit
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
31 Dec 2021
31 Dec 2021
Historique:
received:
10
12
2021
accepted:
28
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
12
1
2022
Statut:
epublish
Résumé
The GIMEMA group investigated the efficacy, safety, and rates of discontinuations of the ibrutinib and rituximab regimen in previously untreated and unfit patients with chronic lymphocytic leukemia (CLL). Treatment consisted of ibrutinib, 420 mg daily, and until disease progression, and rituximab (375 mg/sqm, given weekly on week 1-4 of month 1 and day 1 of months 2-6). This study included 146 patients with a median age of 73 years, with IGHV unmutated in 56.9% and
Identifiants
pubmed: 35008372
pii: cancers14010207
doi: 10.3390/cancers14010207
pmc: PMC8750939
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : AIRC
ID : Progetto 5 per mille
Références
Lancet. 2010 Oct 2;376(9747):1164-74
pubmed: 20888994
Haematologica. 2015 Apr;100(4):e140-2
pubmed: 25616578
Hematol Oncol. 2021 Aug;39(3):326-335
pubmed: 33739461
Haematologica. 2016 Dec;101(12):1448-1450
pubmed: 27903711
Blood. 2014 Mar 20;123(12):1957-60
pubmed: 24652965
Haematologica. 2016 Dec;101(12):1563-1572
pubmed: 27756834
N Engl J Med. 2014 Mar 20;370(12):1101-10
pubmed: 24401022
Lancet Oncol. 2016 Jul;17(7):928-942
pubmed: 27216274
N Engl J Med. 2018 Dec 27;379(26):2517-2528
pubmed: 30501481
Br J Haematol. 2021 Dec 5;:
pubmed: 34865212
Blood. 2019 Mar 7;133(10):1011-1019
pubmed: 30530801
Lancet Oncol. 2014 Sep;15(10):1090-9
pubmed: 25150798
N Engl J Med. 2015 Dec 17;373(25):2425-37
pubmed: 26639149
N Engl J Med. 2019 Aug 1;381(5):432-443
pubmed: 31365801
Leukemia. 2020 Mar;34(3):787-798
pubmed: 31628428
Psychiatry Res. 1992 Mar;41(3):237-48
pubmed: 1594710
Lancet Oncol. 2019 Jan;20(1):43-56
pubmed: 30522969
N Engl J Med. 2013 Jul 4;369(1):32-42
pubmed: 23782158
Haematologica. 2018 May;103(5):874-879
pubmed: 29419429
Blood. 2008 Jun 15;111(12):5446-56
pubmed: 18216293
N Engl J Med. 2014 Jul 17;371(3):213-23
pubmed: 24881631
Haematologica. 2017 Oct;102(10):1796-1805
pubmed: 28751558
N Engl J Med. 2019 Jun 06;380(23):2225-2236
pubmed: 31166681
Haematologica. 2020 Oct 05;106(5):1500-1503
pubmed: 33054124
Blood. 2020 Feb 13;135(7):510-513
pubmed: 31895947
JAMA Oncol. 2015 Apr;1(1):80-7
pubmed: 26182309
Cancer. 2017 Jun 15;123(12):2268-2273
pubmed: 28171709
Haematologica. 2020 Dec 17;107(1):134-142
pubmed: 33327712
Am J Hematol. 2014 May;89(5):480-6
pubmed: 24415640
Clin Lymphoma Myeloma Leuk. 2019 Nov;19(11):715-722.e6
pubmed: 31447270
N Engl J Med. 2020 Jul 30;383(5):498-500
pubmed: 32726539
Leukemia. 2018 May;32(5):1070-1080
pubmed: 29467486
Cancer. 2012 Apr 1;118(7):1827-37
pubmed: 22009554
Front Oncol. 2021 Apr 15;11:637186
pubmed: 33937038
Leukemia. 2017 Jul;31(7):1477-1481
pubmed: 28439111
Leukemia. 2013 Jan;27(1):142-9
pubmed: 23041722
Haematologica. 2016 Dec;101(12):1573-1580
pubmed: 27198718